Previous 10 | Next 10 |
home / stock / bcda / bcda articles
Shares of TransCode Therapeutics, Inc. (NASDAQ: RNAZ) fell sharply during Friday’s session. TransCode Therapeutics priced a 5,942,623 share c...
SUNNYVALE, Calif., Nov. 29, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for th...
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining more than 500 points on Tuesday. The Dow traded up 1.60% to 34,885....
U.S. stocks traded higher midway through trading, with the Dow Jones gaining around 500 points on Tuesday. The Dow traded up 1.42% to 34,833.89 whi...
The FDA approved BioCardia Inc's (NASDAQ: BCDA) Phase 3 CardiAMP Heart Failure II study protocol of CardiAMP autologous cell therapy ...
U.S. stocks traded higher this morning, with the Dow Jones gaining around 400 points on Tuesday. Following the market opening Tuesday, the Dow trad...
U.S. stocks traded mostly lower toward the end of trading, with the Dow Jones falling 100 points on Tuesday. The Dow traded down 0.31% to 34,728.66...
Gainers Verb Technology Company, Inc. (NASDAQ: VERB) shares jumped 164% to $1.89 after the completed and launched a technology integration and st...
U.S. stocks traded mixed midway through trading, with the Nasdaq Composite turning higher on Tuesday. The Dow traded down 0.15% to 34,785.92 while ...
News, Short Squeeze, Breakout and More Instantly...
SUNNYVALE, Calif., July 17, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a company focused on cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases today announces that the Unites States Patent Office has granted Patent No: 12,036,371 ti...
SUNNYVALE, Calif., June 07, 2024 (GLOBE NEWSWIRE) -- BioCardia ® , Inc. [Nasdaq: BCDA], a company focused on cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces that the Unites States Patent Office has granted Patent No: ...